JP2010514796A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514796A5 JP2010514796A5 JP2009544276A JP2009544276A JP2010514796A5 JP 2010514796 A5 JP2010514796 A5 JP 2010514796A5 JP 2009544276 A JP2009544276 A JP 2009544276A JP 2009544276 A JP2009544276 A JP 2009544276A JP 2010514796 A5 JP2010514796 A5 JP 2010514796A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- aryl
- formula
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 87
- 150000001875 compounds Chemical class 0.000 claims description 72
- 125000003118 aryl group Chemical group 0.000 claims description 69
- -1 amino, hydroxyl Chemical group 0.000 claims description 65
- 125000003342 alkenyl group Chemical group 0.000 claims description 62
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 47
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 45
- 125000000304 alkynyl group Chemical group 0.000 claims description 44
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 27
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 25
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 24
- 150000004820 halides Chemical class 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 150000001408 amides Chemical class 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 150000002825 nitriles Chemical class 0.000 claims description 17
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 8
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000005910 alkyl carbonate group Chemical group 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 235000019253 formic acid Nutrition 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- 125000005547 pivalate group Chemical group 0.000 claims description 7
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 claims description 4
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 150000004832 aryl thioethers Chemical class 0.000 claims description 3
- IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 3
- 229940106681 chloroacetic acid Drugs 0.000 claims description 3
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 claims description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 claims description 3
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 3
- 229940013688 formic acid Drugs 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 3
- 125000005039 triarylmethyl group Chemical group 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004319 trichloroacetic acid Drugs 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- MKRZFOIRSLOYCE-UHFFFAOYSA-L zinc;methanesulfonate Chemical compound [Zn+2].CS([O-])(=O)=O.CS([O-])(=O)=O MKRZFOIRSLOYCE-UHFFFAOYSA-L 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 7
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 1
- TVBJMUGQTNVVIW-UHFFFAOYSA-N P(O)(O)(O)=O.C1(CC1)C(=O)O Chemical compound P(O)(O)(O)=O.C1(CC1)C(=O)O TVBJMUGQTNVVIW-UHFFFAOYSA-N 0.000 claims 1
- 229910001115 Zinc-copper couple Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 claims 1
- CVSSUEMSGYVRDI-UHFFFAOYSA-N methanesulfonic acid zinc Chemical compound [Zn].CS(O)(=O)=O.CS(O)(=O)=O CVSSUEMSGYVRDI-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 0 C[C@]1C(CC2)(C(C)(*3)C3(C[C@@](C3CC(*)C4(*5)C5C(*)(*)CC5)C45[Mc])[C@@]23N)O[C@@]2C1N(*)C[C@@](C)C2 Chemical compound C[C@]1C(CC2)(C(C)(*3)C3(C[C@@](C3CC(*)C4(*5)C5C(*)(*)CC5)C45[Mc])[C@@]23N)O[C@@]2C1N(*)C[C@@](C)C2 0.000 description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87801806P | 2006-12-28 | 2006-12-28 | |
| US60/878,018 | 2006-12-28 | ||
| US94159607P | 2007-06-01 | 2007-06-01 | |
| US60/941,596 | 2007-06-01 | ||
| PCT/US2007/088990 WO2008083248A2 (en) | 2006-12-28 | 2007-12-27 | Cyclopamine analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514796A JP2010514796A (ja) | 2010-05-06 |
| JP2010514796A5 true JP2010514796A5 (cg-RX-API-DMAC7.html) | 2011-02-17 |
| JP5412292B2 JP5412292B2 (ja) | 2014-02-12 |
Family
ID=39589207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544276A Active JP5412292B2 (ja) | 2006-12-28 | 2007-12-27 | シクロパミン類似体 |
| JP2009544277A Active JP5542448B2 (ja) | 2006-12-28 | 2007-12-27 | シクロパミン類似体の使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544277A Active JP5542448B2 (ja) | 2006-12-28 | 2007-12-27 | シクロパミン類似体の使用方法 |
Country Status (25)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101487481B1 (ko) | 2004-08-27 | 2015-01-28 | 인피니티 디스커버리, 인코포레이티드 | 사이클로파민 유사체 및 이들의 사용 방법 |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| CA2680186A1 (en) * | 2007-03-07 | 2008-09-12 | Infinity Discovery, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
| MX2009009429A (es) | 2007-03-07 | 2010-07-05 | Infinity Discovery Inc | Analogos de ciclopamina lactama y metodos de uso de los mismos. |
| WO2009086451A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
| AU2008345151A1 (en) * | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Therapeutic cancer treatments |
| US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
| US20100222287A1 (en) * | 2007-12-27 | 2010-09-02 | Mcgovern Karen J | Therapeutic Cancer Treatments |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2009099625A2 (en) * | 2008-02-08 | 2009-08-13 | The Board Of Regents Of The University Of Texas System | Cyclopamine tartrate salt and uses thereof |
| US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
| WO2010085654A1 (en) * | 2009-01-23 | 2010-07-29 | Cancer Research Technology Limited | Hedgehog pathway inhibitors |
| EP2462115B1 (en) | 2009-08-05 | 2016-01-06 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
| US20110065645A1 (en) * | 2009-09-10 | 2011-03-17 | The Regents Of The University Of California | Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance |
| US20110135739A1 (en) * | 2009-11-06 | 2011-06-09 | Bennett Carter | Oral Formulations of a Hedgehog Pathway Inhibitor |
| EP2502078A1 (en) * | 2009-11-20 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| EP2663309B1 (en) | 2011-01-10 | 2017-03-15 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| CA2752008A1 (en) | 2011-09-13 | 2013-03-13 | Universite De Montreal | Combination therapy using ribavirin as elf4e inhibitor |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| PL2782584T3 (pl) | 2011-11-23 | 2021-12-13 | Therapeuticsmd, Inc. | Naturalne skojarzone hormonalne formulacje i terapie zastępcze |
| IN2014MN01945A (cg-RX-API-DMAC7.html) * | 2012-03-06 | 2015-07-10 | Univ Illinois | |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| EP2865663B1 (en) | 2012-06-21 | 2017-04-05 | Eisai R&D Management Co., Ltd. | Novel indanesulfamide derivative |
| MX375194B (es) | 2012-11-01 | 2025-03-06 | Infinity Pharmaceuticals Inc | Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa. |
| CA2893133A1 (en) | 2012-11-29 | 2014-06-05 | Strasspharma Llc | Methods of modulating follicle stimulating hormone activity |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| DK3003309T3 (da) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Behandling af cancer med PI3-kinase-isoform modulatorer |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6518595B2 (ja) | 2013-12-19 | 2019-05-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | １−インダンスルファミド誘導体を含む疼痛の治療および／または予防剤 |
| PT3119397T (pt) | 2014-03-19 | 2022-04-11 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| CN105232562B (zh) * | 2014-07-07 | 2019-06-28 | 中国科学院上海巴斯德研究所 | 一种人呼吸道合胞病毒的抑制剂和抗病毒药物设计靶点 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2988289C (en) | 2015-06-04 | 2023-12-05 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR102787845B1 (ko) | 2015-09-14 | 2025-03-31 | 트웰브 테라퓨틱스, 아이엔씨. | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
| US20170231968A1 (en) * | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
| CN105622708B (zh) * | 2016-02-14 | 2017-10-10 | 山东大学 | 治疗呼吸道合胞病毒感染的化合物及其制备方法与用途 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
| PL3432916T3 (pl) | 2016-09-13 | 2020-04-30 | Allergan, Inc. | Niebiałkowo stabilzowane kompozycje toksyny clostridium |
| SG11202004384YA (en) | 2017-11-17 | 2020-06-29 | Univ Illinois | Cancer therapy by degrading dual mek signaling |
| US12090153B2 (en) | 2018-10-05 | 2024-09-17 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN113461771B (zh) * | 2020-03-31 | 2022-09-30 | 南方科技大学 | 钠钾atp酶抑制剂的制备方法 |
| US12245355B2 (en) | 2021-02-19 | 2025-03-04 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
Family Cites Families (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6333341A (ja) | 1986-07-28 | 1988-02-13 | Seitetsu Kagaku Co Ltd | 配糖体の処理方法 |
| US4843071A (en) | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
| JP2851054B2 (ja) | 1989-03-15 | 1999-01-27 | サントリー株式会社 | ベンズオキセピン誘導体 |
| US5169780A (en) | 1989-06-22 | 1992-12-08 | Celgene Corporation | Enantiomeric enrichment and stereoselective synthesis of chiral amines |
| FR2656310B1 (fr) | 1989-12-22 | 1992-05-07 | Roussel Uclaf | Nouveaux produits sterouides comportant en position 10, un radical thioethyle substitue, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| WO1994020520A1 (en) | 1993-03-10 | 1994-09-15 | Magainin Pharmaceuticals Inc. | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
| IT1265001B1 (it) | 1993-12-16 | 1996-10-17 | Zambon Spa | Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico |
| AU704178B2 (en) | 1993-12-30 | 1999-04-15 | Imperial Cancer Research Technology Ltd | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
| US6281332B1 (en) | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| JPH11514999A (ja) | 1995-10-10 | 1999-12-21 | ストルーブ，マリリン | ビタミンｄおよびその誘導体による掻痒症治療 |
| WO1997020789A1 (en) | 1995-12-06 | 1997-06-12 | Japan Science And Technology Corporation | Process for preparating optically active compounds |
| US6887820B1 (en) | 1995-12-06 | 2005-05-03 | Japan Science And Technology Corporation | Method for producing optically active compounds |
| GB9706321D0 (en) | 1997-03-26 | 1997-05-14 | Zeneca Ltd | Catalytic hydrogenation |
| US6238876B1 (en) | 1997-06-20 | 2001-05-29 | New York University | Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma |
| US7741298B2 (en) | 1997-06-20 | 2010-06-22 | New York University | Method and compositions for inhibiting tumorigenesis |
| US7709454B2 (en) | 1997-06-20 | 2010-05-04 | New York University | Methods and compositions for inhibiting tumorigenesis |
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| US6231875B1 (en) | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
| US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| US6432970B2 (en) | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| US6867216B1 (en) | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
| CA2339330A1 (en) * | 1998-08-13 | 2000-02-24 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
| GB9821067D0 (en) | 1998-09-29 | 1998-11-18 | Zeneca Ltd | Transfer hydrogenation process |
| US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| FR2796938B1 (fr) | 1999-07-29 | 2004-04-02 | Ppg Sipsy | Nouveaux derives chiraux n-substitues de la norephedrine, leur preparation et leur utilisation pour la synthese de composes fonctionnalises optiquement actifs par transfert d'hydrogene |
| CA2385736C (en) | 1999-09-16 | 2011-11-15 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| US20070021493A1 (en) | 1999-09-16 | 2007-01-25 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| US6993456B2 (en) | 1999-09-30 | 2006-01-31 | Rockwell Automation Technologies, Inc. | Mechanical-electrical template based method and apparatus |
| DE60028411T2 (de) | 1999-10-13 | 2007-01-04 | Johns Hopkins University School Of Medicine | Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon |
| US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| JP4898044B2 (ja) | 1999-10-14 | 2012-03-14 | キュリス，インコーポレイテッド | ヘッジホッグシグナル伝達経路のメディエーター、それらと関連する組成物及び利用 |
| US6893637B1 (en) | 1999-10-21 | 2005-05-17 | Zymogenetics, Inc. | Method of treating fibrosis |
| IL133809A0 (en) | 1999-12-30 | 2001-04-30 | Yeda Res & Dev | Steroidal alkaloids and pharmaceutical compositions comprising them |
| KR20010077591A (ko) | 2000-02-03 | 2001-08-20 | 복성해 | 아라니콜라 프로테오리티쿠스에서 분리한 신규 금속성단백질 분해효소 및 그의 유전자 |
| AU4966401A (en) | 2000-03-30 | 2001-10-15 | Curis Inc | Small organic molecule regulators of cell proliferation |
| US6613798B1 (en) | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| EP1387674B1 (en) | 2000-10-13 | 2017-01-18 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| GB0029356D0 (en) | 2000-12-01 | 2001-01-17 | Avecia Ltd | Transfer hydrogenation |
| US6456928B1 (en) | 2000-12-29 | 2002-09-24 | Honeywell International Inc. | Prognostics monitor for systems that are subject to failure |
| DE60220661T2 (de) | 2001-03-16 | 2008-02-14 | Alza Corp., Mountain View | Transdermales pflaster zur verabreichung von fentanyl |
| WO2002080952A2 (en) | 2001-04-09 | 2002-10-17 | Lorantis Limited | Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| AUPR602401A0 (en) | 2001-06-29 | 2001-07-26 | Smart Drug Systems Inc | Sustained release delivery system |
| RU2308948C2 (ru) * | 2001-07-02 | 2007-10-27 | ТАШ Шинан | Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей |
| CA2452152A1 (en) * | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
| DE60113733T2 (de) | 2001-07-02 | 2006-06-29 | Tas, Sinan | Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren |
| MXPA04000803A (es) | 2001-07-27 | 2004-05-21 | Curis Inc | Mediadores de rutas de senalizacion de hedgehog, composiciones y usos relacionados a los mismos. |
| JP2003192919A (ja) * | 2001-10-17 | 2003-07-09 | Asahi Denka Kogyo Kk | 難燃性合成樹脂組成物 |
| EP1446408A1 (en) | 2001-11-09 | 2004-08-18 | Yun Chi | Volatile noble metal organometallic complexes |
| US7105637B2 (en) | 2002-02-15 | 2006-09-12 | William Marsh Rice University | Dehydro-estriol (8-DHE3) and dehydro-pregnanetriol (7-DHPT), methods of their synthesis |
| US20030175355A1 (en) * | 2002-03-07 | 2003-09-18 | Tobyn Michael John | Fast melt multiparticulate formulations for oral delivery |
| JP2005529876A (ja) | 2002-04-22 | 2005-10-06 | ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | Ｈｅｄｇｅｈｏｇシグナル伝達経路の調節因子、それに関連する組成物および使用 |
| GB0210234D0 (en) | 2002-05-03 | 2002-06-12 | Novartis Ag | Process for the manufacture of organic compounds |
| KR20050027095A (ko) | 2002-06-20 | 2005-03-17 | 닛폰 스이산 가부시키가이샤 | 프로드러그, 그 의약으로서의 사용 및 그 제법 |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| GB0221539D0 (en) | 2002-09-17 | 2002-10-23 | Medical Res Council | Methods of treatment |
| GB0230217D0 (en) | 2002-12-27 | 2003-02-05 | Biotica Tech Ltd | Borrelidin-producing polyketide synthase and its uses |
| FR2850022B1 (fr) | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
| EP1639097B1 (en) | 2003-06-25 | 2013-08-07 | Ottawa Health Research Institute | Methods and compositions for modulating stem cell growth and differentiation |
| US20080118493A1 (en) | 2003-07-15 | 2008-05-22 | Beachy Philip A | Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity |
| US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
| US20070231828A1 (en) | 2003-10-01 | 2007-10-04 | Johns Hopkins University | Methods of predicting behavior of cancers |
| US20080095761A1 (en) | 2003-10-01 | 2008-04-24 | The Johns Hopkins University | Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis |
| US20050136449A1 (en) | 2003-10-01 | 2005-06-23 | Invitrogen Corporation | Compositions and methods for synthesizing, purifying, and detecting biomolecules |
| WO2005042700A2 (en) | 2003-10-20 | 2005-05-12 | The Johns Hopkins University | Use of hedgehog pathway inhibitors in small-cell lung cancer |
| US20070219250A1 (en) | 2003-11-28 | 2007-09-20 | Romi Singh | Pharmaceutical Compositions of Nateglinide |
| JP4903133B2 (ja) | 2004-04-30 | 2012-03-28 | ジェネンテック，インコーポレイティド | ヘッジホッグシグナル伝達のキノキサリン阻害剤 |
| KR101487481B1 (ko) * | 2004-08-27 | 2015-01-28 | 인피니티 디스커버리, 인코포레이티드 | 사이클로파민 유사체 및 이들의 사용 방법 |
| KR101225018B1 (ko) | 2004-09-02 | 2013-01-23 | 쿠리스 인코퍼레이션 | 헤지호그 신호전달에 대한 피리딜 억제제 |
| US20070281040A1 (en) | 2004-09-30 | 2007-12-06 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
| CN101083996A (zh) | 2004-10-28 | 2007-12-05 | Irm责任有限公司 | 作为hedgehog途径调节剂的化合物和组合物 |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| US20060252073A1 (en) | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
| CN101291687A (zh) | 2005-05-12 | 2008-10-22 | 因特罗根治疗公司 | 用于癌症治疗的p53疫苗 |
| WO2007024971A2 (en) | 2005-08-22 | 2007-03-01 | The Johns Hopkins University | Hedgehog pathway antagonists to treat disease |
| JP4712524B2 (ja) | 2005-10-28 | 2011-06-29 | 富士通コンポーネント株式会社 | 入力デバイス及び電子機器 |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20070197473A1 (en) | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
| EP1945202A2 (en) | 2005-11-11 | 2008-07-23 | Licentia OY | Mammalian hedgehog signaling inhiabitors |
| AU2006315467B2 (en) | 2005-11-14 | 2013-02-07 | Curis, Inc. | Bisamide inhibitors of hedgehog signaling |
| US20090263317A1 (en) | 2005-12-15 | 2009-10-22 | Wei Chen | Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease |
| US20070179091A1 (en) | 2005-12-27 | 2007-08-02 | Genentech, Inc. | Hedgehog Kinases and Their Use in Modulating Hedgehog Signaling |
| EP1818411A1 (en) | 2006-02-13 | 2007-08-15 | Lonza AG | Process for the preparation of optically active chiral amines |
| US20080019961A1 (en) | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
| US20110034498A1 (en) | 2006-03-24 | 2011-02-10 | Mcgovern Karen J | Dosing regimens for the treatment of cancer |
| CA2648196A1 (en) | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders |
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| DE102006031358A1 (de) * | 2006-07-05 | 2008-01-17 | Schott Ag | Verfahren zur Gehäusung optischer oder optoelektronischer Bauteile, sowie verfahrensgemäß herstellbares optisches oder optoelektronisches Gehäuseelement |
| US20100048944A1 (en) | 2006-07-19 | 2010-02-25 | Farhad Parhami | Interactions of hedgehog and liver x receptor signaling pathways |
| PE20080948A1 (es) | 2006-07-25 | 2008-09-10 | Irm Llc | Derivados de imidazol como moduladores de la senda de hedgehog |
| WO2008037732A1 (en) | 2006-09-29 | 2008-04-03 | Vib Vzw | Plant cell lines established from the medicinal plant veratrum californicum |
| JP2010505877A (ja) | 2006-10-05 | 2010-02-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | スマートな高分子ナノ粒子を用いた低水溶性薬物用の水分散性経口、非経口および局所的製剤 |
| WO2008070357A2 (en) | 2006-10-31 | 2008-06-12 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Smoothened polypeptides and methods of use |
| US20080103116A1 (en) | 2006-11-01 | 2008-05-01 | Jennings-Spring Barbara L | Method of treatment and compositions of D-chiro inositol and phosphates thereof |
| US20080182859A1 (en) | 2006-11-02 | 2008-07-31 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| KR20090087075A (ko) | 2006-11-20 | 2009-08-14 | 사토리 파마슈티컬즈, 인코포레이티드 | 신경변성 장애를 치료하는데 유용한 화합물 |
| US9231784B2 (en) | 2006-11-20 | 2016-01-05 | Thomson Licensing | Method for eliminating redundant connections |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US20100099116A1 (en) | 2007-01-12 | 2010-04-22 | Infinity Discovery, Inc. | Methods for Analysis of Hedgehog Pathway Inhibitors |
| FI123481B (fi) | 2007-02-05 | 2013-05-31 | Upm Kymmene Corp | Menetelmä painopaperin valmistamiseksi ja seoskoostumus |
| CA2680186A1 (en) | 2007-03-07 | 2008-09-12 | Infinity Discovery, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
| MX2009009429A (es) * | 2007-03-07 | 2010-07-05 | Infinity Discovery Inc | Analogos de ciclopamina lactama y metodos de uso de los mismos. |
| JP5577104B2 (ja) | 2007-03-14 | 2014-08-20 | エクセリクシス パテント カンパニー エルエルシー | ヘッジホッグ経路の阻害剤 |
| JP5550352B2 (ja) | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| US9095589B2 (en) | 2007-04-05 | 2015-08-04 | Johns Hopkins University | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors |
| JP5498936B2 (ja) | 2007-04-18 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｓｍｏアンタゴニストであるトリアゾール誘導体 |
| WO2008131354A2 (en) | 2007-04-20 | 2008-10-30 | The Curators Of The University Of Missouri | Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment |
| EP2175863B1 (en) | 2007-07-09 | 2018-03-21 | Eastern Virginia Medical School | Substituted nucleoside derivatives with antiviral and antimicrobial properties |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| WO2009049258A1 (en) * | 2007-10-12 | 2009-04-16 | The Johns Hopkins University | Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies |
| JP5620821B2 (ja) | 2007-12-13 | 2014-11-05 | シエナ ビオテク ソシエタ ペル アチオニＳｉｅｎａ Ｂｉｏｔｅｃｈ Ｓ．Ｐ．Ａ． | ヘッジホッグ経路拮抗薬およびその治療用途 |
| WO2009086451A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
| AU2008345151A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Therapeutic cancer treatments |
| US20100297118A1 (en) | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
| US20100222287A1 (en) | 2007-12-27 | 2010-09-02 | Mcgovern Karen J | Therapeutic Cancer Treatments |
| WO2009099625A2 (en) | 2008-02-08 | 2009-08-13 | The Board Of Regents Of The University Of Texas System | Cyclopamine tartrate salt and uses thereof |
| US20090246841A1 (en) | 2008-03-26 | 2009-10-01 | Jamieson Andrew C | Methods and compositions for production of acetaldehyde |
| US20110217294A1 (en) | 2008-04-11 | 2011-09-08 | Daniel Fults | Combination of hgf inhibitor and hedgehog inhibitor to treat cancer |
| CL2009001479A1 (es) | 2008-07-02 | 2010-01-04 | Infinity Pharmaceuticals Inc | Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide. |
| CA2636807A1 (en) | 2008-07-04 | 2010-01-04 | Steven Splinter | Methods for obtaining cyclopamine |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| JO2889B1 (en) | 2008-09-17 | 2015-03-15 | نوفارتيس ايه جي | Salts 6N - (CIS-2, 6-dimethyl morpholine-4-yl) pyridine-3-yl-methyl-4 ’- (tetrafluoromethoxy) [1,1,-2-phenyl] -3-carboxamide |
| US9206223B2 (en) | 2008-09-22 | 2015-12-08 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
| US20100081637A1 (en) | 2008-10-01 | 2010-04-01 | Innovia Skincare Corp. | Eczema treatment with vitamin D and analogs thereof method, composition and cream |
| WO2010085654A1 (en) | 2009-01-23 | 2010-07-29 | Cancer Research Technology Limited | Hedgehog pathway inhibitors |
| AR077490A1 (es) | 2009-07-21 | 2011-08-31 | Novartis Ag | Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel |
| EP2462115B1 (en) | 2009-08-05 | 2016-01-06 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
| US20110135739A1 (en) * | 2009-11-06 | 2011-06-09 | Bennett Carter | Oral Formulations of a Hedgehog Pathway Inhibitor |
| EP2502078A1 (en) | 2009-11-20 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| WO2011088404A1 (en) | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201010954D0 (en) | 2010-06-29 | 2010-08-11 | Edko Pazarlama Tanitim Ticaret | Compositions |
| US20120010229A1 (en) | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
| WO2012006589A2 (en) | 2010-07-08 | 2012-01-12 | Infinity Pharmaceuticals, Inc. | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| CN102085176A (zh) | 2010-12-31 | 2011-06-08 | 江苏中丹制药有限公司 | 一种纳米级伊曲康唑外用制剂、其制备方法及其用途 |
| US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
| WO2013036830A1 (en) | 2011-09-09 | 2013-03-14 | The Board Of Trustees Of The Leland Standford Junior University | Topical itraconazole formulations and uses thereof |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2014093871A1 (en) | 2012-12-14 | 2014-06-19 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| BR112016021730B1 (pt) | 2014-03-24 | 2022-09-06 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Derivados de quinolina como inibidores de smo |
| CA2988289C (en) | 2015-06-04 | 2023-12-05 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
| US20170231968A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
-
2007
- 2007-12-24 TW TW096149773A patent/TWI433674B/zh active
- 2007-12-27 CN CN200780051112.8A patent/CN101677551B/zh active Active
- 2007-12-27 NZ NZ577916A patent/NZ577916A/xx unknown
- 2007-12-27 MX MX2009007077A patent/MX2009007077A/es active IP Right Grant
- 2007-12-27 CN CN200780051114.7A patent/CN101631463B/zh active Active
- 2007-12-27 BR BRPI0720972A patent/BRPI0720972B8/pt active IP Right Grant
- 2007-12-27 AU AU2007339786A patent/AU2007339786B2/en active Active
- 2007-12-27 JO JO2007564A patent/JO2947B1/en active
- 2007-12-27 JP JP2009544276A patent/JP5412292B2/ja active Active
- 2007-12-27 WO PCT/US2007/088995 patent/WO2008083252A2/en not_active Ceased
- 2007-12-27 CA CA2673995A patent/CA2673995C/en active Active
- 2007-12-27 RU RU2009129000/15A patent/RU2492859C2/ru active
- 2007-12-27 AU AU2007339782A patent/AU2007339782B2/en active Active
- 2007-12-27 PL PL07870001T patent/PL2096917T3/pl unknown
- 2007-12-27 EP EP07870001.0A patent/EP2096917B1/en active Active
- 2007-12-27 BR BRPI0720993A patent/BRPI0720993B8/pt active IP Right Grant
- 2007-12-27 EP EP07870006.9A patent/EP2101580B1/en active Active
- 2007-12-27 SG SG2011096674A patent/SG177930A1/en unknown
- 2007-12-27 MX MX2012007856A patent/MX342683B/es unknown
- 2007-12-27 US US11/965,675 patent/US8017648B2/en active Active
- 2007-12-27 US US11/965,688 patent/US7812164B2/en active Active
- 2007-12-27 NZ NZ578053A patent/NZ578053A/xx unknown
- 2007-12-27 EP EP11165825.8A patent/EP2368551B1/en active Active
- 2007-12-27 KR KR1020097015913A patent/KR101489394B1/ko active Active
- 2007-12-27 MX MX2009007075A patent/MX2009007075A/es active IP Right Grant
- 2007-12-27 ES ES07870001.0T patent/ES2488466T3/es active Active
- 2007-12-27 DK DK07870001.0T patent/DK2096917T3/da active
- 2007-12-27 WO PCT/US2007/088990 patent/WO2008083248A2/en not_active Ceased
- 2007-12-27 EP EP11189894A patent/EP2443926A3/en not_active Withdrawn
- 2007-12-27 RU RU2009128997/04A patent/RU2486194C2/ru active
- 2007-12-27 CA CA2674302A patent/CA2674302C/en active Active
- 2007-12-27 ES ES07870006.9T patent/ES2612746T3/es active Active
- 2007-12-27 SG SG2011096666A patent/SG177929A1/en unknown
- 2007-12-27 JP JP2009544277A patent/JP5542448B2/ja active Active
- 2007-12-27 KR KR1020097015914A patent/KR101482693B1/ko active Active
- 2007-12-27 PT PT78700010T patent/PT2096917E/pt unknown
- 2007-12-27 NO NO20190059A patent/NO347310B1/no unknown
- 2007-12-28 AR ARP070105973A patent/AR081107A1/es active IP Right Grant
- 2007-12-28 CL CL200703854A patent/CL2007003854A1/es unknown
-
2008
- 2008-01-02 PE PE2008000074A patent/PE20090042A1/es active IP Right Grant
- 2008-08-27 US US12/199,689 patent/US8785635B2/en active Active
- 2008-08-27 US US12/199,722 patent/US8669365B2/en active Active
-
2009
- 2009-06-25 ZA ZA2009/04446A patent/ZA200904446B/en unknown
- 2009-06-25 ZA ZA2009/04445A patent/ZA200904445B/en unknown
- 2009-06-25 IL IL199554A patent/IL199554B/en active IP Right Grant
- 2009-07-20 NO NO20092711A patent/NO344315B1/no not_active IP Right Cessation
- 2009-07-20 NO NO20092710A patent/NO343748B1/no unknown
-
2011
- 2011-04-20 US US13/090,694 patent/US20110230509A1/en not_active Abandoned
- 2011-07-27 US US13/191,545 patent/US8227509B2/en active Active
-
2012
- 2012-05-18 US US13/475,510 patent/US20130108583A1/en not_active Abandoned
- 2012-05-18 US US13/475,352 patent/US8895576B2/en active Active
-
2013
- 2013-10-15 US US14/054,350 patent/US9145422B2/en active Active
-
2014
- 2014-03-10 US US14/203,297 patent/US9492435B2/en active Active
-
2015
- 2015-08-31 US US14/841,001 patent/US9669011B2/en active Active
-
2016
- 2016-10-10 US US15/289,887 patent/US9951083B2/en active Active
-
2017
- 2017-05-02 US US15/585,038 patent/US10045970B2/en active Active
-
2018
- 2018-03-27 US US15/936,919 patent/US10406139B2/en active Active
- 2018-07-27 US US16/047,008 patent/US10314827B2/en active Active
-
2019
- 2019-04-26 US US16/396,565 patent/US10821102B2/en active Active
- 2019-07-24 US US16/521,447 patent/US11007181B2/en active Active
-
2020
- 2020-09-28 US US17/035,611 patent/US11602527B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514796A5 (cg-RX-API-DMAC7.html) | ||
| RU2009128997A (ru) | Аналоги циклопамина | |
| ES2566800T3 (es) | Nitrooxiderivados de prostaglandinas | |
| JP2008511635A5 (cg-RX-API-DMAC7.html) | ||
| ES2542728T3 (es) | Composiciones farmacéuticas que tienen la biodisponibilidad deseable | |
| JP2004524340A5 (cg-RX-API-DMAC7.html) | ||
| JP2006501295A5 (cg-RX-API-DMAC7.html) | ||
| JP2006501181A5 (cg-RX-API-DMAC7.html) | ||
| JP2006500394A5 (cg-RX-API-DMAC7.html) | ||
| JP2003531916A5 (cg-RX-API-DMAC7.html) | ||
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| JPWO2020094104A5 (cg-RX-API-DMAC7.html) | ||
| CA2547343A1 (en) | Analogs of benzoquinone-containing ansamycins for the treatment of cancer | |
| RU2006101987A (ru) | Трициклические производные или их фармацевтически приемлемые соли, способы их получения и содержащие их фармацевтические композиции | |
| US20210355082A1 (en) | Method for producing salt | |
| WO2007144169A2 (en) | Entacapone-derivatives | |
| US20160340326A1 (en) | Tizoxanide Carbamate and Pharmaceutical Use Thereof | |
| JP2014505017A5 (cg-RX-API-DMAC7.html) | ||
| JP2009501234A5 (cg-RX-API-DMAC7.html) | ||
| ES2202171T3 (es) | Derivados del acido fosfonico que poseen actividad inhibidora de la carboxipeptidas b. | |
| PT100394A (pt) | Esteres pro-droga de 2-piperidino-1-alcanois fenolicos | |
| CN102105146A (zh) | 用于治疗与暴露于烷化物质有关的损伤的方法 | |
| JP2005514440A5 (cg-RX-API-DMAC7.html) | ||
| ES2733756T3 (es) | Agentes terapéuticos para el tratamiento de hipertensión ocular | |
| JP2007525527A5 (cg-RX-API-DMAC7.html) |